Amyris gained 4 percent to $4.19 at the close in New York, the most since April 1.
The company, based in Emeryville, California, will develop a microorganism that produces a “relevant target molecule” for BASF, according to a statement today. Amyris didn’t say what the molecule will do or provide terms of the deal.
The companies expect the agreement to lead to other joint efforts. Amyris uses genetically modified microorganisms to convert plant sugars into fragrance oils and farnesene, a hydrocarbon that may be processed into fuels or specialty chemicals.
To contact the reporter on this story: Justin Doom in New York at firstname.lastname@example.org
To contact the editors responsible for this story: Reed Landberg at email@example.com Will Wade, Jasmina Kelemen